SCHEMBL6180244

SCHEMBL6180244

O=C(O)c1sc(=O)[nH]c1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
PLA2G10 O15496 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.41
SERPINE1 P05121 1/20 0.41
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 1/20 0.38
PIM1 P11309 1/20 0.38
GFER P55789 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PTPRF P10586 1/20 0.37
PTPN1 P18031 1/20 0.37
CDC7 O00311 1/20 0.37
DBF4 Q9UBU7 1/20 0.37
POLB P06746 2/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15946993 0.80 SMN1; SMN2 (0.40) KDM4EPLA2G10ALDH1A1GAAHPGD
SCHEMBL1929515 0.78 KDM4E (0.51) KDM4EALDH1A1GAAHPGDKMT2A
SCHEMBL11282298 0.78 ALDH1A1 (0.52) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL10703844 0.69 MEN1 (0.52) KDM4EPLA2G10ALDH1A1GAAHPGD
SCHEMBL69825 0.67 GRIA4 (0.50) KDM4EALDH1A1GAAHPGDSMN1; SMN2
SCHEMBL11730396 0.67 HPGD (0.41) KDM4EPLA2G10ALDH1A1GAAHPGD
SCHEMBL15946994 0.67 SMN1; SMN2 (0.45) KDM4EPLA2G10ALDH1A1GAAHPGD
SCHEMBL11730394 0.67 KDM4E (0.41) KDM4EPLA2G10ALDH1A1GAAHPGD
SCHEMBL20376328 0.66 KDM4E (0.46) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL9519626 0.66 GPR35 (0.37) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1291345-B1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors WARNER LAMBERT CO (US) 2005-11-30 EP disclosed
US-6924276-B2 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-08-02 US disclosed
US-20030087924-A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors SORENSON RODERICK JOSEPH (US) 2003-05-08 US disclosed
EP-1291345-A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2003-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087924-A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP3, MMP9 KDM4E 1800/4885PLA2G10 1290/4885ALDH1A1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.